

Commissioner of Patents
USSN 10/661,403

REMARKS

Claims 44 and 45 are pending in the application. Claims 1-43 have been cancelled previously.

Claims 44 and 45 have been further amended to define that the administered oligonucleotide is a phosphorothiated oligonucleotide. Support can be found for example in paragraph [0067] and more specifically, in Table 1 wherein it is clearly indicated that REP 2031 (SEQ ID NO: 22) and REP 2055 (SEQ ID NO: 24) are phosphorothioated oligonucleotides. It is thus believed that no new matter has been hereby introduced and that the claims now on file encompass the full scope of the present invention and clearly defined the structure of the recited oligonucleotides. It is submitted, therefore, that new claims 44 and 45 are in condition for allowance.

No additional fees are believed to be necessitated by this amendment. Should this be in error, authorization is hereby given to charge Deposit Account No. 19-5113 for any underpayment or to credit any overpayment.

In the event that there are any questions concerning this amendment or the application in general, the Examiner is respectfully urged to telephone the undersigned so that prosecution of this application can be expedited.

Respectfully,

Date: September 14, 2007

By: /Christian Cawthorn/

Christian Cawthorn, Reg. No. 47,352
Agent for Applicants

OGILVY RENAULT
1981 McGill College, Suite 1600
Montreal, Quebec H3A 2Y3
CANADA (514) 847-4256